UB-VV500 with rapamycin for advanced multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new cell therapy called UB-VV500 combined with rapamycin for people whose multiple myeloma has returned or not responded to at least three prior treatments. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your myeloma has returned or not responded to treatment with a proteasome inhibitor (like bortezomib), an immunomodulatory drug (like lenalidomide), and an anti-CD38 antibody (like daratumumab).
- You have measurable myeloma after your last cancer therapy.
- You are generally healthy with no serious infections or other major medical conditions.
- You are able to perform daily activities without help (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy, LVIVO-TaVec400, for people with multiple myeloma that has come back or not responded to treatment. The goal is to see if it can help when other treatments have stopped working.
This trial tests a combination of four drugs (elranatamab, isatuximab, bortezomib, and lenalidomide) for people with newly diagnosed, high-risk multiple myeloma. The goal is to see if this combination is safe and effective.
This early-stage trial tests a new therapy called RN9101 for multiple myeloma that has come back or stopped responding to previous treatments. The drug targets a specific protein (BCMA) on myeloma cells and may help patients whose disease has progressed despite earlier therapies.
This trial tests a new intravenous treatment, ABBV-438, for adults with multiple myeloma that has returned or not responded to prior therapies. It aims to see if the drug is safe, tolerable, and how it moves through the body.
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
This trial tests a combination of drugs (isatuximab, bortezomib, lenalidomide, and dexamethasone) for people with newly diagnosed high-risk multiple myeloma who cannot or choose not to have a stem cell transplant. It aims to see if this treatment helps control the disease better.
Hear when a new Multiple Myeloma in Relapse trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.